Primary hormone therapy for locally advanced prostate cancer

Current Urology Reports

Volumn 7, Issue 3, 2006, Pages 225-232

  Swanson, Gregory P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; ESTROGEN; GONADORELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; ORCHIECTOMY; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 33750294967     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-006-0025-x     Document Type: Review

References (41)

1. Walsh PC, DeWeese TL, Eisenberger MA: A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001, 166:508-516.
2. Whitmore WF: Hormone therapy in prostatic cancer. Am J Med 1956, 21:697-712.
3. Huggins C, Hodges CV: Studies on prostate cancer: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:292-297.
4. D'Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. Zelefsky MJ, Fuks Z, Hunt M, et al.: High-dose radiation delivered by intensity-modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876-881.
6. Nesbit RM, Baum WC: Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J Am Med Assoc 1950, 143:1317-1320.
7. Emmett JL, Greene LF, Papantoniou A: Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies. J Urol 1960, 83:471-484.
8. Lepor H, Ross A, Walsh P: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982, 128:335-340.
9. Byar DP: Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973, 32:1126-1130.
10. Blackard CE, Byar DP, Jordon WP: Orchiectomy for advanced prostatic carcinoma: a re-evaluation. Urology 1973, 1:553.
11. Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Urological Research Group studies. NCI Monogr 1988, 7:165-170. Classic randomized study on androgen ablation.
12. Anonymous: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997, 79:235-246. Classic randomized study on androgen ablation.
13. Kirk D: Timing and choice of androgen ablation. Prostate Cancer Prostatic Dis 2004, 7:217-222.
14. Smith PH, Suciu S, Robinson MR, et al.: A comparison of the effect of diethylstilbestrol with low-dose estramustine phosphate in the treatment of advanced prostate cancer: final analysis of a phase-III trial of the European Organization for Research on Treatment of Cancer. J Urol 1986, 136:619-623.
15. Pavone M, de Voogt HJ, Barasolo VE, et al.: Comparison of diethylstilbestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase-III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986, 136:624-631.
16. Oefelein MG, Ricchiuti VS, Conrad PW, et al.: Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 2002, 60:120-124.
17. Fowler JE, Bigler SA, White PC, Duncanc WL: Hormone therapy for locally advanced prostate cancer. J Urol 2002, 168:546-549.
18. Dupont A, Cusan L, Gomez JL, et al.: Combination therapy with flutamide and the LHRH agonist [D-trp6, des-Gly-NH2 10] LHRH ethylamide in stage-C prostate cancer. Br J Urol 1993, 72:629-634.
19. Hachiya T, Koichiro A, Saito S, et al.: A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and northeastern Japan. BJU Int 2005, 95:534-540.
20. Homma Y, Akaza H, Okada K, et al.: Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. Int J Urol 2004, 11:218-224.
21. Studer UE, Whelan P, Albrecht W, et al.: Immediate versus deferred androgen deprivation in patients with asymptomatic prostate cancer T0-4 N0-2 M0 not suitable for local definitive treatment [Abstract 1659]. J Urol 2005, 173:450.
22. Studer UE, Hauri D, Hanselmann S, et al.: Immediate versus deferred hormonal therapy for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004, 22:4109-4118
23. [Erratum in J Clin Oncol 2005, 23:936].
24. Morote J, Trilla E, Esquena S, et al.: Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Can 2004, 108:877-881.
25. Gleave ME, Goldenberg SL, Jones EC, et al.: Biochemical and pathological effects of 8 months of neoadjuvant withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996, 155:213-219.
26. Gleave ME, Goldenberg SL, Chin JL, et al.: Randomized comparative study of 3- versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001, 166:500-507.
27. Soloway MS, Sharifi R, Wajsman Z, et al.: Randomized, prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage-B2 (T2bNxM0) prostate cancer: the Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995, 154:424-428.
28. Klein EA: Hormone therapy for prostate cancer: a topical perspective. Urology 1996, 47(suppl 1A):3-12.
29. Sogani PC, Vagaiwala MR, Whitmore WF: Experience with flutamide in patients with advanced prostate cancer without prior endocrine therapy. Cancer 1984, 54:744-750.
30. Blackledge GR: High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 1996, 47:44-47.
31. Maver FJ, Crawford ED: The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am 1994, 21:707-715.
32. Boccardo F, Rubagotti A, Barichello M, et al.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999, 17:2027-2038.
33. Iversen P, Tyrrell CJ, Kaisary AV, et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer:6.3 years of follow-up. J Urol 2000, 164:1579-1582.
34. Iversen P, Johansson JE, Lodding P, et al.: Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow-up from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004, 172:1871-1876.
35. Wirth MP, See WA, McLeod DG, et al.: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 2004, 172:1865-1870.
36. Kaisary AV: Compliance with hormonal treatment for prostate cancer. Br J Hosp Med 1996, 55:359-366.
37. http://www.hsa.gov.sg/docs/safetyalert_bicalutamide_ Nov03.pdf. Accessed January 27, 2006.
38. Lawton CA, Winter K, Murray K, et al.: Updated results of the phase-III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Biol Phys 2001, 49:937-946.
39. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): phase-III randomized trial. Lancet 2002, 360:103-106.
40. Hanks G, Pajak TF, Porter A, et al.: Phase-III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
41. Herr HW, O'Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743-1746.